3 research outputs found
Egy hazai matematikai felmĂ©rĂ©s eredmĂ©nyei nemzetközi összehasonlĂtĂĄsban
<p><b>Comparisons of the effect of different dipeptidyl peptidase-4 inhibitor treatment for 1 year on adjusted mean changes in fasting plasma glucose (FPG) (A) and glycated hemoglobin (HbA</b><sub><b>1</b></sub><b>c) (B) in the patients with a low and high hemoglobin glycation index (HGI).</b> Factors included in the analysis of variance statistical model were baseline oral anti-diabetes drugs, age, sex and renal function. VI = vildagliptin (n = 24 in the low HGI and n = 36 in the high HGI groups), LI = linagliptin (n = 33 in the low HGI and n = 31 in the high HGI groups), SA = saxagliptin (n = 45 in low HGI and n = 64 in the high HGI groups), SI = sitagliptin (n = 97 in the low HGI and n = 138 in the high HGI group). Error bars represent 95% confidence interval (CI). p-value for between-group difference. (To convert glucose to millimoles per liter, multiply by 0.0555)</p
Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes - Fig 1
<p><b>Mean value from baseline to 1 year of dipeptidyl peptidase-4 inhibitor treatment in two groups according to baseline hemoglobin glycation index (HGI) in fasting plasma glucose (FPG) (<i>p</i> = 0.965) (A) and glycated hemoglobin (HbA</b><sub><b>1</b></sub><b>c) (<i>p</i> < 0.001) (B).</b> Data are presented as mean ± standard deviation (SD). * p = 0.002, **p<0.001 compared with baseline; where â<i>p</i>â represents <i>p</i>-value of between-group difference. (To convert glucose to millimoles per liter, multiply by 0.0555.)</p
Demographic and baseline characteristics of the study participant.
<p>Demographic and baseline characteristics of the study participant.</p